HRP20170810T1 - Peptidi i spojevi koji se vežu za receptore trombopoietina - Google Patents

Peptidi i spojevi koji se vežu za receptore trombopoietina Download PDF

Info

Publication number
HRP20170810T1
HRP20170810T1 HRP20170810TT HRP20170810T HRP20170810T1 HR P20170810 T1 HRP20170810 T1 HR P20170810T1 HR P20170810T T HRP20170810T T HR P20170810TT HR P20170810 T HRP20170810 T HR P20170810T HR P20170810 T1 HRP20170810 T1 HR P20170810T1
Authority
HR
Croatia
Prior art keywords
compound
cells
use according
sarcosine
nal
Prior art date
Application number
HRP20170810TT
Other languages
English (en)
Croatian (hr)
Inventor
Brian R. Macdonald
Jeffery Kenneth Weis
Edward John Yurkow
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of HRP20170810T1 publication Critical patent/HRP20170810T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
HRP20170810TT 2003-08-28 2004-08-13 Peptidi i spojevi koji se vežu za receptore trombopoietina HRP20170810T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
EP04781153.4A EP1675606B1 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (1)

Publication Number Publication Date
HRP20170810T1 true HRP20170810T1 (hr) 2017-08-11

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170810TT HRP20170810T1 (hr) 2003-08-28 2004-08-13 Peptidi i spojevi koji se vežu za receptore trombopoietina

Country Status (32)

Country Link
US (1) US7576056B2 (enExample)
EP (1) EP1675606B1 (enExample)
JP (1) JP4848277B2 (enExample)
KR (2) KR101183875B1 (enExample)
CN (2) CN102241742B (enExample)
AR (1) AR045530A1 (enExample)
AU (1) AU2004270656B2 (enExample)
BR (1) BRPI0414008B8 (enExample)
CA (1) CA2537421C (enExample)
CY (1) CY1118965T1 (enExample)
DK (1) DK1675606T3 (enExample)
EA (1) EA009286B1 (enExample)
EC (1) ECSP066396A (enExample)
ES (1) ES2626107T3 (enExample)
HR (1) HRP20170810T1 (enExample)
HU (1) HUE032370T2 (enExample)
IL (1) IL173965A (enExample)
IS (1) IS8300A (enExample)
LT (1) LT1675606T (enExample)
ME (1) ME00313B (enExample)
MX (1) MXPA06002292A (enExample)
NO (1) NO344233B1 (enExample)
NZ (1) NZ545455A (enExample)
PL (1) PL1675606T3 (enExample)
PT (1) PT1675606T (enExample)
RS (2) RS56387B1 (enExample)
SG (1) SG131110A1 (enExample)
SI (1) SI1675606T1 (enExample)
TW (1) TWI348375B (enExample)
UA (1) UA82710C2 (enExample)
WO (1) WO2005023834A2 (enExample)
ZA (1) ZA200602495B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
DK1783222T3 (da) 1998-10-23 2012-07-09 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
UA82710C2 (uk) 2003-08-28 2008-05-12 Орто-Макнейл Фармацевтикал, Инк. Пептид, що зв'язується з тромбопоетиновим рецептором (варіанти), та спосіб лікування тромбоциторенії (варіанти)
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
TWI458488B (zh) * 2006-02-14 2014-11-01 Janssen Pharmaceutica Nv Tpo胜肽化合物及醫藥組成物於治療貧血之用途
CN101374540B (zh) * 2006-02-14 2013-03-06 詹森药业有限公司 Tpo肽化合物和药物组合物在治疗贫血中的用途
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2307041B1 (en) * 2008-06-03 2019-03-13 Janssen Pharmaceutica, N.V. Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment
JP5709113B2 (ja) 2011-06-23 2015-04-30 株式会社島津製作所 分岐型両親媒性ブロックポリマー、それを用いた分子集合体及び薬剤搬送システム
EP3658191A1 (en) * 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020209920A2 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
JP7664163B2 (ja) 2019-01-25 2025-04-17 ヤンセン ファーマシューティカ エヌ.ベー. 全身照射/化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
CA3234340A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
CA2150371C (en) 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
CZ221496A3 (en) 1994-02-14 1997-07-16 Zymogenetics Inc Haematopoetic protein, materials and processes for preparing thereof
HU218893B (hu) 1994-03-31 2000-12-28 Amgen Inc. A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
WO1996014293A1 (en) * 1994-11-04 1996-05-17 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivative having hydroxyl group
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
EP0783003B1 (en) 1995-04-26 2006-11-22 Kyowa Hakko Kogyo Co., Ltd. G-CSF TPO fusion proteins
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CZ291749B6 (cs) * 1995-06-07 2003-05-14 Glaxo Group Limited Peptidová sloučenina, která se váže na thrombopoetinový receptor a aktivuje jej a farmaceutický prostředek
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
JP2003509462A (ja) 1999-09-24 2003-03-11 スミスクライン・ビーチャム・コーポレイション トロンボポイエチン模倣物
WO2002051861A2 (en) * 2000-12-22 2002-07-04 Kinerton Limited Process for the synthesis of a peptide having a tryptophan residue
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
UA82710C2 (uk) 2003-08-28 2008-05-12 Орто-Макнейл Фармацевтикал, Инк. Пептид, що зв'язується з тромбопоетиновим рецептором (варіанти), та спосіб лікування тромбоциторенії (варіанти)

Also Published As

Publication number Publication date
RS20060141A (sr) 2008-08-07
PT1675606T (pt) 2017-05-22
BRPI0414008B1 (pt) 2018-05-15
ME00313B (me) 2011-05-10
EP1675606A4 (en) 2009-09-30
DK1675606T3 (en) 2017-06-19
AU2004270656A1 (en) 2005-03-17
SI1675606T1 (sl) 2017-07-31
JP4848277B2 (ja) 2011-12-28
EP1675606A2 (en) 2006-07-05
UA82710C2 (uk) 2008-05-12
CN1871022A (zh) 2006-11-29
LT1675606T (lt) 2017-11-10
IL173965A (en) 2015-10-29
MEP48508A (en) 2011-02-10
ES2626107T3 (es) 2017-07-24
IL173965A0 (en) 2006-07-05
CN102241742B (zh) 2014-04-02
KR101183875B1 (ko) 2012-09-27
KR20120078742A (ko) 2012-07-10
TW200517103A (en) 2005-06-01
ZA200602495B (en) 2007-06-27
CA2537421C (en) 2011-09-27
US20050137133A1 (en) 2005-06-23
NO344233B1 (no) 2019-10-14
NO20061346L (no) 2006-05-22
SG131110A1 (en) 2007-04-26
JP2007504132A (ja) 2007-03-01
HUE032370T2 (en) 2017-09-28
WO2005023834A2 (en) 2005-03-17
US7576056B2 (en) 2009-08-18
MXPA06002292A (es) 2006-09-04
KR20070017942A (ko) 2007-02-13
RS56387B1 (sr) 2017-12-29
CN102241742A (zh) 2011-11-16
AU2004270656B2 (en) 2011-03-10
NZ545455A (en) 2009-02-28
BRPI0414008A (pt) 2006-10-24
BRPI0414008B8 (pt) 2021-05-25
TWI348375B (en) 2011-09-11
HK1096873A1 (en) 2007-06-15
CN1871022B (zh) 2011-07-06
WO2005023834A3 (en) 2005-05-06
EA009286B1 (ru) 2007-12-28
AR045530A1 (es) 2005-11-02
CY1118965T1 (el) 2018-01-10
IS8300A (is) 2006-02-14
PL1675606T3 (pl) 2017-08-31
EP1675606B1 (en) 2017-04-05
EA200600477A1 (ru) 2007-02-27
CA2537421A1 (en) 2005-03-17
ECSP066396A (es) 2006-08-30

Similar Documents

Publication Publication Date Title
HRP20170810T1 (hr) Peptidi i spojevi koji se vežu za receptore trombopoietina
EP2726115B1 (en) Procoagulant peptides and their derivatives and uses therefor
EP3337523B1 (en) Preventative therapy for post-traumatic osteoarthritis
ES2703826T3 (es) Inmunoterapia con IL-12 destinada al cáncer
US20060115457A1 (en) Biocompatible hydrogel compositions
US20230226142A1 (en) Ionic self-assembling peptides
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
WO2011069141A2 (en) Interferon therapies in combination with blockade of stat3 activation
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
EP2601241A1 (en) Absorbable peg-based hydrogels
AU2016211457A1 (en) Joint fat pad formulations, and methods of use thereof
US20160022872A1 (en) Cell-based compositions, cell-based bandage devices and systems and methods of treatment therewith
JP2007504132A5 (enExample)
US7297676B2 (en) Thymosin alpha 1 peptide/polymer conjugates
CA2380216C (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
JP2009504650A5 (enExample)
ES2607986T3 (es) Agentes terapéuticos para regular el fósforo en suero
AU2002363248B2 (en) Method of administering a Thymosin alpha 1 peptide
AU2009208481B2 (en) Pharmaceutical composition and combined agent
EP1648398A2 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
Ubhe IL-1 receptor antagonist: etiological and drug delivery systems overview
WO2018022457A1 (en) Accelerated healing by injectable multi-arm branched amphiphilic scaffolds loaded with hydrophobic drugs
WO2025175399A1 (en) Conductive benzoic acid based polymer containing biomaterial for repairing nervous system injury
WO2022182920A1 (en) Osteotropic compositions and uses thereof
Gavard An innovative hyaluronic acid product for viscosupplementation in patients with osteoarthritis